Pilot Study of Hypertrophic Cardiomyopathy & Implantable Cardioverter Defibrillator Assessment: (Subcutaneous vs Transvenous) (HICD)
Implantable Defibrillator User, Hypertrophic Cardiomyopathy, Implantable Cardioverter Ventricular Lead Dysfunction or Complication
About this trial
This is an interventional treatment trial for Implantable Defibrillator User focused on measuring Transvenous Implantable Defibrillator, Subcutaneous Implantable Defibrillator
Eligibility Criteria
Inclusion Criteria: Hypertrophic Cardiomyopathy and a referred for ICD therapy with no pacing requirement. Exclusion Criteria: Patients with sustained ventricular tachycardia less than 170 bpm Patients having an indication for pacing therapy. E.g. sick sinus syndrome. Patients failing appropriate QRS/T-wave sensing with the automated S-ICD ECG automated patient screening provided by Boston Scientific A minimum of 1 sensing vector passing in supine, standing. Patients with incessant ventricular tachycardia Patients who have had a previous ICD implant Patient who receives cardiac contractility modulation therapy or are likely to receive cardiac contractility modulation therapy Patients with a serious known concomitant disease with a life expectancy of less than one year Patients with circumstances that prevent follow-up (no permanent home or address, transient, etc.) Patients who are unable to give informed consent Patients who are not suitable for TV-ICD implantation, according to the discretion of the physician, are not screened for enrolment (SVC occlusion).
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Transvenous Implantable Defibrillator
Subcutaneous Implantable Defibrillator
Routine TV ICD implant
SICD ICD implant as per study protocol